G1 Therapeutics Inc $ 21.37 0.56 (2.69%)
Volume:
975,480
Avg Vol (1m):
1,402,966
Market Cap $:
813.04 Mil
Enterprise Value $:
602.50 Mil
P/E (TTM):
0.00
P/B:
4.12
Financial Strength | 6/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 8.57 | ||
Equity-to-Asset | 0.77 | ||
Debt-to-Equity | 0.14 | ||
Debt-to-EBITDA | -0.24 | ||
Piotroski F-Score | 3 | ||
Altman Z-Score | 5.53 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -379.07 | ||
Net Margin % | -380.49 | ||
ROE % | -46.63 | ||
ROA % | -39.9 | ||
ROC (Joel Greenblatt) % | -922.15 | ||
3-Year EBITDA Growth Rate | -32.2 | ||
3-Year EPS without NRI Growth Rate | -26.1 |
GTHX
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 4.12 | ||
PS Ratio | 28.23 | ||
EV-to-EBIT | -5.25 | ||
EV-to-EBITDA | -5.28 | ||
EV-to-Revenue | 20.96 | ||
Current Ratio | 7.45 | ||
Quick Ratio | 7.45 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 4.12 | ||
Earnings Yield (Greenblatt) % | -19.05 |